...
首页> 外文期刊>EFSA Journal >Assessment of Echinococcus?multilocularis surveillance reports submitted in 2017 in the context of Commission Regulation (EU) No?1152/2011
【24h】

Assessment of Echinococcus?multilocularis surveillance reports submitted in 2017 in the context of Commission Regulation (EU) No?1152/2011

机译:根据欧盟法规(EU)第1152/2011号对2017年提交的多球棘球chin虫病监测报告进行评估

获取原文
   

获取外文期刊封面封底 >>

       

摘要

This report is part of the ‘Echinococcus multilocularis surveillance’ scientific reports which are presented annually by EFSA to the European Commission and are intended to assess the sampling strategy, data collection and detection methods used by Finland, Ireland, Malta, the UK and Norway in their respective surveillance programmes. The surveillance programmes of these five countries were evaluated by checking the information submitted by each of them and verifying that the technical requirements laid down in Regulation (EU) No 1152/2011 were complied. The information was divided into four different categories for assessment: the type and sensitivity of the detection method, the selection of the target population, the sampling strategy and the methodology. For each category, the main aspects that need to be taken into account in order to accomplish the technical requirements of the legislation were checked against compliance of several criteria. All of the territories participating in this surveillance (Finland, the UK, Norway, Malta and Ireland) succeeded in the fulfilment of the technical legal requirements foreseen in Regulation (EU) No 1152/2011 concerning these four different categories. However, both Malta and Northern Ireland (UK) fulfil those requirements only assuming a diagnostic test sensitivity value higher than the one suggested by EFSA (conservative value of 0.78). None of the five countries recorded positive samples in 2016.
机译:该报告是EFSA每年向欧洲委员会提交的“多球菌监测”科学报告的一部分,旨在评估芬兰,爱尔兰,马耳他,英国和挪威在2006年使用的采样策略,数据收集和检测方法。他们各自的监视程序。通过检查每个国家/地区提交的信息并验证是否符合法规(EU)1152/2011规定的技术要求,对这五个国家/地区的监视计划进行了评估。信息分为四个不同的评估类别:检测方法的类型和敏感性,目标人群的选择,抽样策略和方法。对于每个类别,为了符合立法的技术要求,都需要考虑几个主要方面的合规性。参与此监视的所有区域(芬兰,英国,挪威,马耳他和爱尔兰)都成功满足了针对这四个不同类别的第(EU)1152/2011号法规中规定的技术法律要求。但是,马耳他和北爱尔兰(英国)均满足这些要求,前提是诊断诊断灵敏度值要高于EFSA建议的灵敏度(保守值0.78)。五个国家/地区在2016年均未录得阳性样本。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号